337 related articles for article (PubMed ID: 19519336)
21. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Majem M; Pallarès C
Clin Transl Oncol; 2013 May; 15(5):343-57. PubMed ID: 23359171
[TBL] [Abstract][Full Text] [Related]
22. Current management of advanced non-small cell lung cancer: targeted therapy.
Isobe T; Herbst RS; Onn A
Semin Oncol; 2005 Jun; 32(3):315-28. PubMed ID: 15988686
[TBL] [Abstract][Full Text] [Related]
23. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
24. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Pirker R; Minar W; Filipits M
Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
[TBL] [Abstract][Full Text] [Related]
27. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
Kelly K; Huang C
J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
29. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
30. [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Lind JS; Herder GJ; Smit EF
Ned Tijdschr Geneeskd; 2008 Apr; 152(16):928-32. PubMed ID: 18561788
[TBL] [Abstract][Full Text] [Related]
31. Targeted Therapy for NSCLC--A Double-edged Sword?
Dempke WC
Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
[TBL] [Abstract][Full Text] [Related]
32. [Targeted therapies and radiation therapy in non-small cell lung cancer].
Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
[TBL] [Abstract][Full Text] [Related]
33. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Mendoza L
Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
[TBL] [Abstract][Full Text] [Related]
35. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
36. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
37. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
38. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
39. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.
Cascone T; Morelli MP; Ciardiello F
Ann Oncol; 2006 Mar; 17 Suppl 2():ii46-48. PubMed ID: 16608981
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]